SCHEMBL19212170

SCHEMBL19212170

Cc1cc(C(F)F)c(C#N)c(=S)[nH]1

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HAVCR2 Q8TDQ0 1/20 0.61
ALDH1A1 P00352 11/20 0.50
HPGD P15428 7/20 0.50
KDM4E B2RXH2 9/20 0.46
HSD17B10 Q99714 7/20 0.46
MAPT P10636 6/20 0.46
GAA P10253 5/20 0.46
APOBEC3G Q9HC16 5/20 0.46
ALOX15 P16050 5/20 0.46
TP53 P04637 2/20 0.46
GLA P06280 2/20 0.38
RXFP1 Q9HBX9 1/20 0.37
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
ATM Q13315 1/20 0.31
RECQL P46063 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9820043 0.76 HAVCR2 (1.00) HAVCR2ALDH1A1HPGDKDM4EHSD17B10
SCHEMBL19583298 0.74 CUL4A (0.50) HAVCR2ALDH1A1HPGDKDM4EHSD17B10
SCHEMBL4888217 0.72 ALDH1A1 (0.66) HAVCR2ALDH1A1HPGDKDM4EHSD17B10
SCHEMBL5233820 0.70 HAVCR2 (0.62) HAVCR2ALDH1A1HPGDKDM4EHSD17B10
SCHEMBL26566413 0.64 RECQL (0.33) RECQL
SCHEMBL13277489 0.63 KDM4E (0.54) HAVCR2ALDH1A1HPGDKDM4EHSD17B10
SCHEMBL20339837 0.62 KDM4E (0.57) ALDH1A1HPGDKDM4EHSD17B10GAA
SCHEMBL4196229 0.62 KDM4E (0.38) ALDH1A1HPGDKDM4EHSD17B10MAPT
SCHEMBL15691382 0.61 NTRK1 (0.35) ALDH1A1KDM4EMAPTGAARECQL
SCHEMBL13058619 0.59 GABRA1 (0.40) ALDH1A1HPGDKDM4EMAPTRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10913753-B2 Thienopyridine carboxamides as ubiquitin-specific protease inhibitors VALO EARLY DISCOVERY, INC. (US) 2021-02-09 US disclosed
EP-3414252-A1 THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS Forma Therapeutics, Inc. (US) 2018-12-19 EP disclosed
WO-2017139778-A1 THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS FORMA THERAPEUTICS, INC. (US) 2017-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10913753-B2 Thienopyridine carboxamides as ubiquitin-specific protease inhibitors USP28, USP25, USP24 HAVCR2 3674/4885ALDH1A1 2323/4885HPGD 2536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.